EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Genomma Lab InternacionalB de CV's enterprise value is MXN19,562 Mil.
Genomma Lab InternacionalB de CV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN3,504 Mil. Therefore, Genomma Lab InternacionalB de CV's EV-to-EBITDA for today is 5.58.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's EV-to-EBITDA or its related term are showing as below:
MEX:LABB'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.5 Med: 7.44 Max: 17.12
Current: 5.58
During the past 13 years, the highest EV-to-EBITDA of Genomma Lab InternacionalB de CV was 17.12. The lowest was -29.50. And the median was 7.44.
MEX:LABB's EV-to-EBITDA is ranked better than 84.05% of 740
companies
in the Drug Manufacturers industry
Industry Median: 12.955
vs MEX:LABB: 5.58
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Genomma Lab InternacionalB de CV (MEX:LABB) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genomma Lab InternacionalB de CV's PE Ratio (TTM) for today is calculated as:
Genomma Lab InternacionalB de CV's share price for today is MXN15.33.
Genomma Lab InternacionalB de CV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN1.644.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV EV-to-EBITDA Chart
MEX:LABB vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's EV-to-EBITDA falls into.
Genomma Lab InternacionalB de CV's current Enterprise Value is MXN19,562 Mil.
Genomma Lab InternacionalB de CV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3,504 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genomma Lab InternacionalB de CV (MEX:LABB) has a EV-to-EBITDA of 5.58 as of Jul. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genomma Lab InternacionalB de CV. This is 25% below median its historical median of 7.44. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #118 out of 740 companies in the Drug Manufacturers industry, placing it in the top 15.9%.
Is Genomma Lab InternacionalB de CV's EV-to-EBITDA too high?
Genomma Lab InternacionalB de CV's current EV-to-EBITDA of 5.58 is 25% below median its 10-year median of 7.44. The Drug Manufacturers industry median EV-to-EBITDA is 12.96. Genomma Lab InternacionalB de CV's value of 5.58 is 56.9% below this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #118 out of 740 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #118 out of 740 companies for EV-to-EBITDA. This places Genomma Lab InternacionalB de CV in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 12.96. Genomma Lab InternacionalB de CV's value of 5.58 is 56.9% below this benchmark. While the company's 10-year median is 7.44 vs. the industry median of 12.96, Genomma Lab InternacionalB de CV has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 740 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current EV-to-EBITDA of 5.58 is 56.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Genomma Lab InternacionalB de CV. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current EV-to-EBITDA is 5.58, which is 25% below median its own 10-year median of 7.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.66, compared to a current price of MXN15.33 — trading 13.2% below its estimated fair value. The current EV-to-EBITDA is 5.58, which is 25% below median its 10-year median of 7.44 and 56.9% below the Drug Manufacturers industry median of 12.96. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current EV-to-EBITDA is 5.58 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.33 is trading 13.2% below its estimated GF Value™ of MXN17.66.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
EV-to-EBITDA: 5.58 (25% below median its 10-year median of 7.44)
GF Value™: MXN17.66 vs. price of MXN15.33 (13.2% below fair value)
Industry Position: 56.9% below the Drug Manufacturers median (#118 of 740)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
